Inhibikase Therapeutics (IKT) Competitors $1.71 -0.02 (-1.16%) Closing price 04:00 PM EasternExtended Trading$1.71 0.00 (0.00%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKT vs. ATYR, BCYC, ZVRA, MBX, EOLS, ALMS, CMPX, TECX, KOD, and ETONShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include aTyr Pharma (ATYR), Bicycle Therapeutics (BCYC), Zevra Therapeutics (ZVRA), MBX Biosciences (MBX), Evolus (EOLS), Alumis (ALMS), Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), Kodiak Sciences (KOD), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. Its Competitors aTyr Pharma Bicycle Therapeutics Zevra Therapeutics MBX Biosciences Evolus Alumis Compass Therapeutics Tectonic Therapeutic Kodiak Sciences Eton Pharmaceuticals aTyr Pharma (NASDAQ:ATYR) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Which has better earnings and valuation, ATYR or IKT? aTyr Pharma is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr PharmaN/AN/A-$64.02M-$0.80-6.84Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.64 Does the media refer more to ATYR or IKT? In the previous week, aTyr Pharma had 6 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for aTyr Pharma and 0 mentions for Inhibikase Therapeutics. aTyr Pharma's average media sentiment score of 0.88 beat Inhibikase Therapeutics' score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media. Company Overall Sentiment aTyr Pharma Positive Inhibikase Therapeutics Neutral Do institutionals and insiders have more ownership in ATYR or IKT? 61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 3.7% of aTyr Pharma shares are owned by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility and risk, ATYR or IKT? aTyr Pharma has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Is ATYR or IKT more profitable? aTyr Pharma's return on equity of -93.69% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -93.69% -68.83% Inhibikase Therapeutics N/A -350.63%-201.82% Do analysts prefer ATYR or IKT? aTyr Pharma currently has a consensus target price of $23.25, suggesting a potential upside of 325.05%. Inhibikase Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 280.12%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe aTyr Pharma is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryaTyr Pharma beats Inhibikase Therapeutics on 11 of the 14 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$127.42M$282.63M$5.76B$21.30BDividend YieldN/AN/A6.66%3.50%P/E Ratio-0.64N/A83.0129.44Price / SalesN/A477.76503.0564.27Price / CashN/A22.4425.7018.29Price / Book0.9611.4110.795.30Net Income-$19.03M-$115.81M$3.29B$998.51M7 Day Performance-7.07%2.35%0.01%0.12%1 Month Performance6.87%1.01%7.06%5.75%1 Year Performance26.67%-14.14%50.09%14.88% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics1.7743 of 5 stars$1.71-1.2%$6.50+280.1%+29.1%$127.42MN/A-0.646Gap UpATYRaTyr Pharma2.4079 of 5 stars$5.38+0.6%$23.25+332.2%+220.8%$527.17M$230K-6.7253News CoverageOptions VolumeGap UpBCYCBicycle Therapeutics2.9431 of 5 stars$7.38+4.2%$22.22+201.1%-65.9%$511.09M$35.28M-2.10240Positive NewsZVRAZevra Therapeutics3.1158 of 5 stars$9.07-2.5%$23.71+161.5%+22.2%$509.14M$23.61M-43.1920Positive NewsShort Interest ↑MBXMBX Biosciences2.5816 of 5 stars$15.09+5.7%$37.63+149.3%N/A$506.93MN/A-3.3236News CoveragePositive NewsEOLSEvolus4.5294 of 5 stars$7.63+1.5%$21.25+178.5%-52.6%$493.55M$266.27M-7.79170News CoveragePositive NewsShort Interest ↓ALMSAlumis2.5714 of 5 stars$4.64-1.3%$20.17+334.6%-61.6%$482.86MN/A0.00N/ACMPXCompass Therapeutics2.696 of 5 stars$3.49flat$12.89+269.3%+123.2%$482.61M$850K-7.7620News CoveragePositive NewsTECXTectonic Therapeutic2.2755 of 5 stars$25.54-0.1%$80.33+214.5%-14.9%$477.91MN/A-6.32120News CoveragePositive NewsAnalyst ForecastKODKodiak Sciences3.8097 of 5 stars$9.04+0.8%$11.75+30.0%+254.1%$477.51MN/A-2.3890Positive NewsETONEton Pharmaceuticals2.5725 of 5 stars$17.31+0.2%$29.67+71.4%+279.3%$464.21M$39.01M-108.1920News CoveragePositive News Related Companies and Tools Related Companies ATYR Alternatives BCYC Alternatives ZVRA Alternatives MBX Alternatives EOLS Alternatives ALMS Alternatives CMPX Alternatives TECX Alternatives KOD Alternatives ETON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IKT) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
